Merck KGaA will acquire Bio-Techne for $73 per share in cash, representing a total deal value of approximately $11.3 billion, marking the German multinational science and tech company’s largest acquisition in over a decade.
The two companies are complementary, offering bioprocessing technologies to support customers across the spectrum of life science workflows — from discovery and translational research through development, testing and commercial manufacturing.
"Building on our strong track record in the Life Science Business, this transaction strengthens our presence in some of the most exciting and fastest-growing areas of the life sciences, including multi-omics, spatial biology, precision diagnostics and cell and gene therapy," said Jean-Charles Wirth, Merck KGaA board member and CEO of the Life Science division.
Aside from its portfolio of GMP-grade cytokines, nonviral gene delivery systems, stem cell and organoid culture reagents, and precision analytical instruments, Bio-Techne has also partnered with Wilson Wolf to offer ScaleReady, a standardized scale-up solution already used in approved CAR-T therapies on the market.
This is Merck KGaA’s largest M&A deal since it acquired Sigma-Aldrich in a $17 billion buyout in 2015.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!